jack tool kit price perform life scienc tool
diagnost industri
trivia question last year flu season eclips ili outpati
visit month decemb
recent note report life scienc tool dx weekli flu clue review ili
w/w decemb mammographi market model
climb higher mettler toledo consist compound rich multipl initi
equal weight life scienc tool dx outlook stock select critic
oper sentiment align
barclay geograph end market tracker agil pmi tracker
q/q pmi tracker q/q thermo fisher pmi
tracker q/q water pmi tracker q/q
strengthen w/w chines yuan strengthen w/w japanes yen
hot topic week pmi data decemb remain robust level
us manufactur pmi ism regist inc research inventiv
announc cfo greg rush resign pursu opportun privat
compani kingm diagnost announc partnership develop
applic chines market
life scienc tool diagnost industri finish week sinc
last thursday tool diagnost lab
comparison week russel
nasdaq composit
stat week flu season full swing cdc report
outpati visit relat influenza-lik ill ili
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
pleas present barclay life scienc tool diagnost trivia question
week week ask question tool diagnost industri
would prefer dont look answer wont polic simpl answer
next week weekli
trivia question last year flu season eclips ili outpati
visit month decemb
last week answer life scienc tool diagnost industri out-perform
 last year similar out-performance
group increas vs
jack tool kit life scienc tool diagnost
week answer question receiv client tri pick
topic respons dont pick question keep tri get
question price perform life scienc tool
diagnost industri
life scienc tool diagnost industri significantli outperform
 rel notabl compani
broader industri post posit return life scienc tool sub-
segment deliv return strong perform across group illumina
best perform agil mettler toledo
outperform peer diagnost finish year averag
establish compani finish year finish
driven mostli acquisit triage/bnp lab
finish year averag lead group
scienc tool dx lab avgholx cynosur acquisit patheonacquisit novaseq introduct chilternacquisit draft rate releas merger announc triage/bnp acquisit acquir pamplonacapit symphoni acquisit genesightrct result investor day rebrand barclay life scienc tool diagnost
look throughout year
life scienc tool diagnost industri outperform
rel perform across sector posit
life scienc tool diagnost well lab
outperform tool led group
increas driven optim relat novaseq launch compani
outperform howev diagnost led foundat medicin
across lab health
best perform inc research/ inventiv laggard
industri outperform rel
perform strong across three sub-sector led lab
increas tool broad base growth off-set
diagnost show mix perform
quarter though group lab growth broad
base led inc research inventiv optim
driven acceler quarter
industri line vs index
perform rel consist across coverag tool growth
driven agil thermo fisher
diagnost show vari strength lab
growth primarili driven cro group icon notabl
lab declin
industri slightli under-perform rel
 tool group led
perform diagnost moder foundat medicin
quarter
genmark show sharp declin lab mix
strong perform health off-set weaker perform
number compani includ inc research/ invent
thomson one barclay research past perform necessarili indic futur result
life scienc tool diagnost support innov healthcar
believ lead outsiz industri growth cycl sinc
lead sequenc first human genom life scienc group
outperform year believ robust growth reflect
innov technolog manufactur substanti opportun ahead still
tremend need demand life scienc diagnost industri tool
support genom forens agricultur safeti product diseas detect
compani document barclay research past perform necessarili indic futur result
section summar recent research public pleas contact us
copi
 life scienc tool diagnost weekli flu clue review ili
w/w decemb
publish edit barclay health flu clue review
weekli report track sever progress flu season follow three
metric percentag patient visit physician attribut
perform avgdiagnost avglab cro avg barclay life scienc tool diagnost
influenza-lik ill ili versu baselin averag influenza-lik ill defin
fever exceed degre plu either cough sore throat percentag death
attribut pneumonia influenza versu baselin averag number
type posit influenza test conduct clinic laboratori report
center diseas control cdc us world organ
nation respiratori viru surveil nrevss edit examin data
week end decemb week week flu season
obtain data cdc feder govern agenc part
human servic hh depart
week fda publish decemb updat industri mammographi trend
end almost exactli line expect placement forecast
industri keep mind calendar fourth quarter year typic
season weak given rsna confer decemb data publish monthli
mammographi qualiti standard act mqsa program provid way
extern valid momentum mammographi placement data
encourag near-term result remain cautiou around us placement
opportun convers instal base believ low-single-digit
breast health growth driven servic intern new product caveat
data obvious perfect fda survey hospit imag center
annual basi data lumpi said placement rate industri
mammographi volum trend give us insight industri test rate remain
signific debat industri
geograph pmi improv decemb remain healthi expansionari level
lend support thesi industri end market show sign
improv except m/m pmi show healthi
improv m/m europ m/m germani m/m
japan m/m china pmi broadli remain expansionari territori
across market view healthi read industri end market
coverag beyond improv pmi perform view china attract end
market life scienc tool compani given countri invest area well-
align coverag notabl biopharmaceut life scienc research well
higher environment standard favor agil thermo fisher life scienc
tool coverag believ better industri commentari could lead improv revenu
growth remind revenu gener life scienc tool compani
highli correl end market growth compani individu geographi
consist compound rich multipl initi
initi coverag equal weight rate price target
view strong oper consist strategi proven
good invest time life scienc tool compani
market leader precis weigh analyt instrument servic laboratori
industri retail market sever characterist improv visibl
growth potenti near term compani market leader
product segment compet mettler toledo dispar custom base
disciplin sale strategi allow differenti unit price growth time
recent growth acceler given exposur core industri market well
invest long-term societ need consist free cash flow gener given
manag flexibl pursu consist capit deploy strategi favor
tuck-in share repurchas combin factor
consist compound invest outperform last year
averag annual return period vs
critic oper sentiment align januari
look believ stock select life scienc tool diagnost becom
import oper sentiment appear align coverag
banner year stock perform group averag vs
believ biopharma end market remain growth driver support
invest push toward person medicin drive demand bioproduct cdx
differenti offer biggest potenti risk pick-up
biopharma consolid strong macro datapoint provid quarter visibl
industri end market momentum import growth driver tool coverag
healthcar sustain driver volum growth includ popul growth age
demograph emerg market access increas adopt genomic/esoter
test new risk implement pama believ cut
consolid major theme coverag final bipartisan support
academ fund continu drive lsd trend coverag
pmi data decemb remain robust level us manufactur pmi
ism regist
inc research inventiv announc cfo greg rush resign pursu
opportun privat compani
kingm diagnost announc partnership develop applic
chines market
help investor gaug end market activ develop barclay pmi
tracker tracker repres weighted-averag growth agil
thermo fisher underli geographi use pmi data ism unit
state markit intern one-quart lag barclay agil
thermo fisher pmi tracker correl
organ growth follow quarter respect
pleas reach us would like copi barclay pmi tracker
decemb barclay agil pmi tracker regist
q/q approxim agil revenu gener outsid unit
state exposur asia europ compani barclay
agil pmi end market tracker one-quart lead correl
compani organ growth rate notic trend agil geograph
exposur growth past quarter far back intern data
track believ pmi tracker best use one-quart lead indic
expansionari tracker perform start year give us good convict
agil abil hit initi guidanc organ growth
barclay pmi tracker regist q/q
approxim compani revenu gener outsid unit state
signific exposur emerg market revenu barclay
perkinelm pmi end market tracker one-quart lead correl
compani organ growth rate notic trend perkinelm
geograph exposur growth past quarter far back intern
data track believ pmi tracker best use one-quart lead
indic note recent lower guidanc
barclay thermo fisher pmi tracker regist q/q
approxim thermo fisher revenu gener outsid unit state
exposur china revenu germani uk amongst
other barclay thermo fisher end market tracker one-quart lead
correl compani organ growth rate optic notic
trend thermo fisher geograph exposur growth past quarter
far back intern data track believ pmi tracker best use
one-quart lead indic note solid pmi tracker perform
similar thermo fisher organ growth guidanc
barclay water pmi tracker regist q/q approxim
revenu gener outsid unit state exposur europ
revenu asia amongst other barclay water end market
tracker one-quart lead correl compani organ growth
rate optic notic trend geograph exposur
growth past quarter far back intern data track
believ pmi tracker best use one-quart lead indic note
expansionari read pmi tracker perform similar water expect
organ growth repres growth upper end life
vi price perform valuat updat
life scienc tool diagnost industri finish week sinc last
thursday tool diagnost lab
comparison week russel
nasdaq composit genmark best perform stock group
follow contrast foundat medicin worst
perform stock broadli speak week posit stock
increas stock decreas current level enterpris valu tool
ebitda diagnost trade lab trade
enterpris valu life scienc tool compani near twelv month
ntm ebitda estim rang varian
compar averag ntm ebitda averag
past year group broadli trade rang forward ebitda
enterpris valu diagnost compani trade ntm ebitda
estim rang compar
five-year averag ntm ebitda ten-year averag past
five year group broadli trade within rang forward ebitda
enterpris valu cro compani trade ntm ebitda estim
rang inc research health compar five-year
averag ntm ebitda ten-year averag past five year
group broadli trade within rang forward ebitda
enterpris valu lab compani trade ntm ebitda estim
compar five-year averag ntm ebitda ten-year averag
past five year group broadli trade rang forward ebitda
price target base multipl ebitda estim materi discuss valuat methodolog avail upon request full disclosur
cover compani includ detail company-specif valuat methodolog risk pleas refer http //publicresearch barcap com
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
viii stat week
flu season full swing cdc report outpati visit
relat influenza-lik ill ili
ix week life scienc tool diagnost
section present news summari relev articl past week
myriad genet announc expand research collabor astrazeneca
wednesday myriad genet announc astrazeneca use compani
mychoic hrd exploratori analysi identifi women advanc ovarian
cancer may benefit mainten treatment lynparza olaparib avastin
bevacizumab financi term disclos agreement myriad use
mychoic hrd test evalu patient enrol on-going phase trial
collabor compani use mychoic hrd test identifi case
holog receiv ce mark myosur manual devic europ wednesday
announc myosur manual devic design simplifi
tissu remov procedur regardless set receiv ce mark europ
myosur manual devic join myosur suit gynaecolog surgic product
offer simpl effect solut resect remov tissu
pleas reach us barclay sale repres sign-up
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
